CAR T-cell Therapy CT103A Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.

Read the full article here

Related Articles